Addex Therapeutics (ADXN) vs Longeveron (LGVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Addex Therapeutics is the larger company by market cap ($6.1 million vs $5.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADXN | LGVN |
|---|---|---|
| Share price | $3.47 | $1.66 |
| Market cap | $6.08M | $5.60M |
| 1-day change | +2.06% | -8.79% |
| EPS (TTM) | $-7.56 | $-7.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.20M |
| Revenue growth (YoY) | — | -49.87% |
| Net income (latest FY) | — | $-22.70M |
| Gross margin | — | 66.97% |
| Operating margin | — | -1942.20% |
| Net margin | — | -1893.58% |
| 52-week high | $10.43 | $12.30 |
| 52-week low | $2.56 | $1.31 |
| Distance from 52-week high | -66.73% | -86.50% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +3589.76% |
| Average volume | 383.35K | 115.35K |
| Shares outstanding | 1.75M | 3.23M |
| Employees | 3 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Addex Therapeutics
ADXN stock →Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
ADXN vs LGVN FAQ
Which is bigger, Addex Therapeutics or Longeveron?
Addex Therapeutics (ADXN) is larger, with a market capitalization of $6.08M compared with $5.60M for Longeveron (LGVN).
Are Addex Therapeutics and Longeveron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.